March 19 (Reuters) - Crinetics Pharmaceuticals said on Tuesday its experimental drug to treat a hormonal disorder met the main goal in a late-stage study. (Reporting by Sneha S K; Editing by Shilpi Majumdar)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
42.82 USD | +1.66% | -1.84% | +19.84% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.84% | 3.32B | |
+2.62% | 42.75B | |
+47.70% | 41.61B | |
+12.39% | 41.34B | |
-12.36% | 26.59B | |
+8.37% | 25.49B | |
-23.28% | 18.12B | |
+30.45% | 12.24B | |
-1.90% | 11.76B | |
+7.78% | 11B |
- Stock Market
- Equities
- CRNX Stock
- News Crinetics Pharmaceuticals, Inc.
- Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study